DARE Dare Bioscience Inc.

+0.07  (7%)
Previous Close 0.95
Open 0.99
Price To book 0.28
Market Cap 6173204
Shares 6,052,161
Volume 363,744
Short Ratio 0.35
Av. Daily Volume 494,371

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to be initiated 2H 2018.
Female Sexual Arousal Disorder (FSAD)

Latest News

  1. Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive 
  2. Daré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference
  3. Daré Bioscience, Inc. To Participate in the LD Micro Virtual Conference
  4. Daré Bioscience, Developing Products for Women, Analysts Target, Pipeline Review
  5. Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder
  6. Daré Bioscience, Inc. to raise approximately $10.25 million
  7. Today’s Research Reports on Trending Tickers: Dare Bioscience and MannKind
  8. Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
  9. Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder
  10. Daré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor Conference
  11. Sabrina Martucci Johnson Joins Aethlon Medical's Board of Directors
  12. Who Are The Major Shareholders Of Daré Bioscience Inc (DARE)?
  13. With An ROE Of 177.59%, Has Daré Bioscience Inc’s (DARE) Management Done A Good Job?
  14. Daré Bioscience Inc (DARE): Is Healthcare Attractive Relative To NasdaqCM Peers?